ENDRA Life Sciences Inc. filings document a Nasdaq-listed medical technology issuer focused on thermoacoustic biomarker imaging and the TAEUS® Liver device for liver fat assessment in steatotic liver disease, MASLD and MASH. Periodic and current reports disclose operating results, clinical-program updates, research and development spending, liquidity, risk factors and common-stock registration matters.
The company’s SEC record also covers material-event reports on private placement financing, at-the-market equity offering arrangements, digital asset treasury disclosures involving HYPE token holdings, supplemental digital-asset risk factors, Nasdaq continued-listing compliance, workforce-related exit costs and strategic-review matters. Proxy materials document director elections, equity incentive plan amendments, auditor matters and other stockholder voting items.
ASP Isotopes Inc., ENDRA Life Sciences Inc., Renergen Limited and Noble Africa are promoting an investor webinar on July 21, 2026, to discuss a proposed merger between Noble Africa, a wholly owned ASP Isotopes subsidiary, and ENDRA. If completed, the merger and related transactions are expected to result in Noble Africa becoming a Nasdaq-listed public company under the ticker "NOBA," creating a helium- and LNG-focused platform centered on Renergen’s Virginia Gas Project in South Africa.
The webinar will feature Paul Mann, CEO of ASP Isotopes and Renergen and expected CEO of Noble Africa following the transactions, outlining the Virginia Gas Project’s roadmap, including the anticipated ramp to Phase 1 nameplate production in 2026, a planned Phase 2 expansion, and key operational and financing milestones. The communication also explains that ENDRA will file a Form S-4 with the SEC containing a proxy statement and prospectus and emphasizes that investors should review those materials when available, while highlighting extensive forward-looking statement and risk-factor disclosures related to the Proposed Transactions.
ENDRA Life Sciences and ASP Isotopes describe a previously signed Agreement and Plan of Merger under which Noble Africa, currently a wholly owned ASP Isotopes subsidiary and holding company for Renergen Limited, is proposed to merge with ENDRA. If the Proposed Transactions close, Noble Africa is expected to become a Nasdaq-listed public company trading under the ticker "NOBA."
The communication promotes a July 21, 2026 investor webinar, featuring ASP Isotopes and Renergen CEO Paul Mann, focused on Renergen’s Virginia Gas Project, described as one of the world’s highest-grade commercial helium resources and a dual-revenue platform combining helium and LNG. The text outlines anticipated Phase 1 production ramp in 2026, a planned Phase 2 expansion, and emphasizes that detailed information about the Proposed Transactions will be provided in a future Form S-4 registration statement and related proxy materials to be filed with the SEC.
ENDRA Life Sciences Inc. reports that Nasdaq has notified the company it has regained compliance with the exchange’s minimum stockholders’ equity requirement of $2,500,000 under Nasdaq Listing Rule 5550(b)(1). This follows an earlier notice of deficiency based on the company’s Form 10-K for the year ended December 31, 2025.
Under Nasdaq Listing Rule 5815(d)(4)(A), the company will be subject to a one-year Discretionary Panel Monitor period starting July 1, 2026. If ENDRA falls out of compliance with any Nasdaq listing rule during this monitoring period, it will not receive additional time to cure but would instead receive a Delist Determination Letter, with only the opportunity to request another hearing before a Nasdaq Hearings Panel.
ENDRA Life Sciences director Anthony DiGiandomenico has updated his Schedule 13D to reflect a new voting agreement tied to a planned merger. He beneficially owns 196,692 shares of ENDRA common stock, which is 9.99% of the company when including certain options and warrants he can exercise.
The filing describes a merger agreement under which a subsidiary of ENDRA will merge with Noble Africa LLC, leaving Noble as a wholly owned subsidiary. In connection with this, DiGiandomenico agreed to vote his shares for issuing new Class A and Class B common stock as merger consideration, a potential reverse stock split to maintain Nasdaq compliance, a new equity incentive plan, and an amended and restated certificate of incorporation that would rename the company Noble Africa Inc. He also granted ENDRA an irrevocable proxy if he does not vote as agreed and is subject to a statutory cooling-off period after entering into the voting agreement.
ENDRA Life Sciences entered a definitive merger agreement to combine with Noble (an ASP Isotopes affiliate) and to be renamed Noble Africa Inc. The transaction contemplates a merger of Merger Sub into Noble, a concurrent equity financing (the Noble Investment) expected to raise approximately $50 million, and the contribution of ASPI’s interest in Renergen in exchange for 55,500,000 Class B Units of Noble.
The A&R Certificate of Incorporation will create dual-class common stock (Class A and Class B), with Class B shares carrying 10 votes per share. Closing is conditioned on stockholder approval, SEC effectiveness of a Form S-4 registration statement, Nasdaq listing approval, receipt of financing proceeds and other customary conditions; the agreement may be terminated if not closed by December 24, 2026.
ENDRA Life Sciences agreed to merge with Noble Africa LLC, an ASP Isotopes subsidiary that will hold South African helium and LNG company Renergen. Before the merger, Noble plans a private investment of approximately $50 million by selling 4,594,218 Class A units or pre-funded warrants and 3,054,185 Class B units at $6.57 per unit.
At closing, Noble will become a wholly owned subsidiary of ENDRA, which will be renamed Noble Africa Inc. and adopt a dual-class structure with Class A and Class B common stock, with Class B carrying ten votes per share. ASPI will receive 55,500,000 Class B units of Noble, later convertible into Class B common stock. ENDRA may implement a reverse stock split to maintain Nasdaq compliance and will seek stockholder approval for the merger consideration, the reverse split, a new equity plan and a new charter.
The merger is subject to conditions including ENDRA stockholder approval, SEC effectiveness of a Form S-4, Nasdaq listing of the new shares, completion of the $50 million Noble financing, OPIC consent under an existing finance agreement, ASPI’s contribution of Renergen and ENDRA holding at least $3.8 million of cash. The outside date for closing is December 24, 2026, and either party can terminate if key conditions, including stockholder approval, are not met.
ASP Isotopes Inc. entered into an Agreement and Plan of Merger with ENDRA Life Sciences Inc., pursuant to which ENDRA’s subsidiary Merger Sub will merge with Noble Africa LLC, with Noble surviving as a direct, wholly owned subsidiary of ENDRA. Concurrently, Noble agreed to a $50 million financing through subscription agreements for approximately 4,594,218 Class A Units (and/or pre-funded warrants) and the Company will receive 3,054,185 Class B Units in the financing and will contribute its equity interest in Renergen to Noble for 55,500,000 Class B Units. At the Effective Time ENDRA will be renamed Noble Africa Inc. and adopt an amended charter establishing Class A and Class B common stock (Class B votes 10 votes per share). Closing conditions include ENDRA stockholder approval, SEC effectiveness of a Form S-4, Nasdaq listing approval, receipt of Noble Investment proceeds, a written OPIC/DFC consent where required, and ENDRA having at least $3.8 million of cash. The Merger Agreement may be terminated if not closed by December 24, 2026.
ENDRA Life Sciences Inc. disclosed a proposed merger of its subsidiary with Noble Africa LLC on June 25, 2026.
The filing states the proposed transaction involves Noble Africa LLC, a wholly‑owned subsidiary of ASP Isotopes, Inc., described as an intermediate holding company for Renergen Limited. A press release is furnished as Exhibit 99.1 and is incorporated by reference.
ENDRA Life Sciences has announced a proposed merger in which its subsidiary will combine with Noble Africa LLC, a wholly owned ASP Isotopes unit that holds Renergen’s helium interests. Noble Africa would be the surviving entity and the combined company plans to trade on Nasdaq as “NOBA.”
Alongside the merger, Noble Africa has secured commitments for a concurrent private placement expected to raise approximately $50 million in gross proceeds, including about $20 million from ASP Isotopes and about $30 million from other investors, such as $750,000 from ASP Isotopes directors and management. At closing, ASP Isotopes is expected to own roughly 89% of the combined company, pre-closing ENDRA stockholders about 3%, and other private placement investors about 7%.
The transactions have been approved by both boards and are expected to close in the third or fourth quarter of 2026, subject to ENDRA stockholder approval, SEC effectiveness of a Form S-4 registration statement, and other customary conditions. The combined company would operate as Noble Africa Inc. with a board primarily designated by ASP Isotopes.